{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T14:09:13Z","timestamp":1792246153054,"version":"4.4.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","license":[{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Children with Down syndrome (DS) have a higher risk of developing acute leukemia than do those without DS. There are few studies in the literature about outcome, survival, and difficulties of treating patients with DS and acute leukemia in a developing country. This study aimed to analyze the outcome, response to treatment, survival, treatment complications, and causes of death in patients with DS and acute leukemia compared with those in patients with acute leukemia without DS diagnosed in the same period of time.<\/jats:p>\n            <jats:p>We conducted a retrospective observational analysis including a cohort of 21 patients with DS and acute leukemia diagnosed between 2009 and 2018 in 3 hemato-oncology centers (2 pediatric centers and 1 adult hematology center). A group of patients with DS-acute lymphoblastic leukemia (DS-ALL) was analyzed and compared with a group of 165 patients with acute lymphoblastic leukemia without DS, and a group of patients with DS-acute myeloid leukemia (DS-AML) was analyzed and compared with a group of 50 patients with acute myeloid leukemia without DS, which was diagnosed during the same period of time (2009\u20132018) and treated under similar conditions in terms of both treatment protocols and economic resources.<\/jats:p>\n            <jats:p>The overall survival rates in children with DS-ALL and DS-AML were 35.7% and 57.1%, respectively (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.438). The overall survival rate was significantly worse in children with DS-ALL than in those with acute lymphoblastic leukemia without DS (35.71% vs 75.80%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.001). We noted that treatment-related mortality in the patients with DS-ALL was high (50%) (infections and toxicities related to chemotherapy); this result was significantly different from that for patients with leukemia without DS (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.0001). The relapse rate was higher in patients with DS-ALL but not significantly higher than that in patients without DS (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.13).<\/jats:p>\n            <jats:p>In contrast, the overall survival rate was better for patients with DS-AML than for those with acute myeloid leukemia without DS (57.1% vs 45.1%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.47).<\/jats:p>\n            <jats:p>Because of the particularities of the host, we suggest that DS-ALL and DS-AML should be considered as independent diseases and treated according to specific protocols with therapy optimization per the minimal residual disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000027459","type":"journal-article","created":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T13:31:44Z","timestamp":1633699904000},"page":"e27459","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":20,"title":["Outcomes of patients with Down syndrome and acute leukemia"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1985-903X","authenticated-orcid":false,"given":"Madalina-Petronela","family":"Schmidt","sequence":"first","affiliation":[{"name":"\u201cSf Maria\u201d Children's Hospital-Hemato-Oncology Department, Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Colita","sequence":"additional","affiliation":[{"name":"Fundeni Clinical Institut - Pediatrics Department, Bucharest, Romania"},{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca-Viorica","family":"Ivanov","sequence":"additional","affiliation":[{"name":"\u201cSf Maria\u201d Children's Hospital-Hemato-Oncology Department, Iasi, Romania"},{"name":"\u201cGrigore T Popa\u201d University of Medicine and Pharmacy, Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Coriu","sequence":"additional","affiliation":[{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy, Bucharest, Romania"},{"name":"Fundeni Clinical Institut-Hematology Department, Bucharest, Romania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrith-Crenguta","family":"Miron","sequence":"additional","affiliation":[{"name":"\u201cSf Maria\u201d Children's Hospital-Hemato-Oncology Department, Iasi, Romania"},{"name":"\u201cGrigore T Popa\u201d University of Medicine and Pharmacy, Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,10,8]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bjh.13096","article-title":"Haematopoietic development and leukemia in Down syndrome","volume":"167","author":"Roberts","year":"2014","journal-title":"Br J Haematol"},{"key":"R2-20250504","first-page":"76","article-title":"Down syndrome and leukemia: insights into leukemogenesis and translational targets","volume":"4","author":"Mateos","year":"2015","journal-title":"Transl Pediatr"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1182\/blood-2013-07-515148","article-title":"GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia","volume":"122","author":"Roberts","year":"2013","journal-title":"Blood"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/ng.2759","article-title":"The landscape of somatic mutations in Down syndrome-related myeloid disorders","volume":"45","author":"Yoshida","year":"2013","journal-title":"Nat Genet"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1365-2141.2005.05906.x","article-title":"Treatment for myeloid leukemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials","volume":"132","author":"Rao","year":"2006","journal-title":"Br J Haematol"},{"key":"R6-20250504","first-page":"608","article-title":"Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: children's Cancer Group Studies 2861 and 2891","volume":"91","author":"Lange","year":"1998","journal-title":"Blood"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/sj.leu.2403188","article-title":"Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93","volume":"18","author":"Lehrnbecher","year":"2004","journal-title":"Leukemia"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/blood.V87.8.3395.bloodjournal8783395","article-title":"Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia","volume":"87","author":"Taub","year":"1996","journal-title":"Blood"},{"key":"R9-20250504","first-page":"1393","article-title":"Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin","volume":"94","author":"Taub","year":"1999","journal-title":"Blood"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2005-06-2219","article-title":"Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia","volume":"107","author":"Ge","year":"2006","journal-title":"Blood"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/jnci\/dji026","article-title":"GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia","volume":"97","author":"Ge","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1046\/j.1365-2141.2000.02027.x","article-title":"The management of neoplastic disorders of haematopoiesis in children with Down's syndrome","volume":"110","author":"Lange","year":"2000","journal-title":"Br J Haematol"},{"issue":"(suppl)","key":"R13-20250504","first-page":"05","article-title":"Down syndrome and leukemia","volume":"6","author":"Robison","year":"1992","journal-title":"Leukemia"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2013-07-453480","article-title":"How I treat ALL in Down's syndrome: pathobiology and management","volume":"123","author":"Izraeli","year":"2014","journal-title":"Blood"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/blood-2009-08-235408","article-title":"Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group","volume":"115","author":"Hertzberg","year":"2010","journal-title":"Blood"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1182\/blood-2007-09-114231","article-title":"Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study","volume":"111","author":"Forestier","year":"2008","journal-title":"Blood"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood-2013-06-509463","article-title":"Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno Study Group","volume":"123","author":"Buitenkamp","year":"2014","journal-title":"Blood"},{"key":"R18-20250504","first-page":"2737","article-title":"Baseline characteristics of a nationwide cohort of pediatric patients with acute leukemias of Down syndrome","volume":"25","author":"Sas","year":"2020","journal-title":"JBUON"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood-2013-03-491621","article-title":"Results of the AIEOP AML 2002\/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia","volume":"122","author":"Pession","year":"2013","journal-title":"Blood"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood.V116.21.181.181","article-title":"Study AML-BFM. 2004: improved survival in childhood acute myleloid leukemia without increased toxicity","volume":"116","author":"Creutzig","year":"2010","journal-title":"Blood"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1182\/blood-2017-01-765057","article-title":"Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial","volume":"129","author":"Uffmann","year":"2017","journal-title":"Blood"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1200\/JCO.2013.48.6522","article-title":"Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL-IC-BFM 2002","volume":"32","author":"Stary","year":"2014","journal-title":"J Clin Oncol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S0889-8588(05)70188-X","article-title":"Treatment of adult ALL according to protocols of German multicenter study group for adult ALL (GMALL)","volume":"14","author":"Gokbuget","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1182\/blood.V104.11.1952.1952","article-title":"Childhood standard risk B cell precursor acute lymphoblastic leukemia (SR-BCP-ALL): toxicity and efficacy interim results of the FRALLE 2000 protocol","volume":"104","author":"Baruchel","year":"2004","journal-title":"Blood"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","article-title":"Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia","volume":"129","author":"Theunissen","year":"2017","journal-title":"Blood"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-1-4939-6703-2_6","article-title":"Chromosome bandings","volume":"1541","author":"Huang","year":"2017","journal-title":"Methods Mol Biol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"e27256","DOI":"10.1002\/pbc.27256","article-title":"Outcome of children and adolescents with Down Syndrome treated on Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium protocols 00-001 and 05-001","volume":"65","author":"Athale","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/MPH.0000000000000540","article-title":"Pharmacokinetics of chemotherapeutic drugs in pediatric patients with Down syndrome and leukemia","volume":"38","author":"Hefti","year":"2016","journal-title":"J Pediatr Hematol Oncol"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1182\/hematology.2019000017","article-title":"Moving immunotherapy into the front line in ALL","volume":"2019","author":"Winters","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"e27644","DOI":"10.1002\/pbc.27644","article-title":"Need for new thinking: treatment of relapsed leukemia in children with down syndrome","volume":"66","author":"Rabin","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"(suppl)","key":"R34-20250504","first-page":"1280","article-title":"CTL019 therapy appears safe and effective in pediatric patients with Down syndrome with relapsed\/refractory (r\/r) acute lymphoblastic leukemia","volume":"130","author":"Laetsch","year":"2017","journal-title":"Blood"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.phoj.2020.03.003","article-title":"Japan Children's Cancer Group: international collaborations and plans","volume":"5","author":"Okamoto","year":"2020","journal-title":"Pediatr Hematol Oncol J"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.canep.2018.10.004","article-title":"Characteristics and survival of children with acute leukemia with Down syndrome or other birth defects in New York State","volume":"57","author":"Qiao","year":"2018","journal-title":"Cancer Epidemiol"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1182\/blood-2017-01-764324","article-title":"Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial improved","volume":"129","author":"Taub","year":"2017","journal-title":"Blood"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1097\/MPH.0000000000001158","article-title":"Epigenetic therapy in a patient with Down syndrome and refractory acute myeloid leukemia","volume":"41","author":"Becktell","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/pbc.26062","article-title":"Hematologic response to vorinostat treatment in relapsed myeloid leukemia of Down syndrome","volume":"63","author":"Scheer","year":"2016","journal-title":"Pediatr Blood Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027459","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:33:19Z","timestamp":1746340399000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027459"}},"subtitle":["A retrospective observational study"],"short-title":[],"issued":{"date-parts":[[2021,10,8]]},"references-count":38,"journal-issue":{"issue":"40","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000027459","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,8]]},"assertion":[{"value":"2021-05-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}